Dermira, Inc. (DERM) Sees Unusually-High Trading Volume

Dermira, Inc. (NASDAQ:DERM) saw unusually-high trading volume on Tuesday . Approximately 1,659,019 shares changed hands during mid-day trading, an increase of 350% from the previous session’s volume of 368,697 shares.The stock last traded at $28.67 and had previously closed at $27.24.

DERM has been the topic of several analyst reports. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on shares of Dermira in a report on Tuesday, July 18th. Mizuho reaffirmed a “buy” rating and issued a $43.00 target price (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, BidaskClub downgraded shares of Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.40.

The firm’s 50 day moving average is $25.49 and its 200 day moving average is $28.52. The stock’s market cap is $1.19 billion.

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.00 million. On average, analysts expect that Dermira, Inc. will post ($4.20) EPS for the current year.

In related news, CEO Thomas G. Wiggans sold 9,500 shares of the stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $27.51, for a total value of $261,345.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Fred B. Craves bought 30,000 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was bought at an average price of $23.03 per share, with a total value of $690,900.00. The disclosure for this purchase can be found here. Insiders sold a total of 11,800 shares of company stock valued at $319,751 in the last quarter. 13.30% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc grew its position in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares in the last quarter. Alliancebernstein L.P. grew its position in Dermira by 4.5% in the 1st quarter. Alliancebernstein L.P. now owns 41,600 shares of the biopharmaceutical company’s stock valued at $1,419,000 after buying an additional 1,800 shares in the last quarter. Nationwide Fund Advisors grew its position in Dermira by 6.5% in the 1st quarter. Nationwide Fund Advisors now owns 30,609 shares of the biopharmaceutical company’s stock valued at $1,044,000 after buying an additional 1,867 shares in the last quarter. SG Americas Securities LLC grew its position in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in Dermira by 12.8% in the 2nd quarter. ProShare Advisors LLC now owns 24,682 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 2,808 shares in the last quarter. Hedge funds and other institutional investors own 97.56% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/10/10/dermira-inc-derm-sees-unusually-high-trading-volume.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply